Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3b, 42-day, Randomized, Double-Blind, Placebo Controlled, Parallel Group Study to Evaluate the Safety and Tolerability of Nebulized Revefenacin and Nebulized Formoterol Fumarate (PERFOROMIST) Administered in Sequence and as a Combined Solution in Subjects With Chronic Obstructive Pulmonary Disease

Next Previous
Search
Trial Profile

A Phase 3b, 42-day, Randomized, Double-Blind, Placebo Controlled, Parallel Group Study to Evaluate the Safety and Tolerability of Nebulized Revefenacin and Nebulized Formoterol Fumarate (PERFOROMIST) Administered in Sequence and as a Combined Solution in Subjects With Chronic Obstructive Pulmonary Disease

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 11 May 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Formoterol (Primary) ; Revefenacin (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Adverse reactions; Registrational
  • Sponsors Theravance Biopharma

    • Most Recent Events

    • 21 Oct 2020 Results of subgroup analysis assessing tolerability, Safety, and Lung Function Response presented at the CHEST Annual Meeting 2020 by Annual Meeting of the American College of Chest Physicians
    • 20 Nov 2018 Status changed from active, no longer recruiting to completed.
    • 14 Aug 2018 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top